LEAH Labs

Living therapies for pets first, and their people next

Y CombinatorWinter 2019ActiveHealthcareTherapeuticsCRISPRCell TherapyDrug discovery

What they do

Problem

Dogs with B cell lymphoma lack accessible, affordable curative treatments and are often limited to palliative care or specialist referral.

Solution

A virus-free gene-edited CAR-T cell therapy platform that produces low-cost doses for treating canine B cell lymphoma with curative potential.

Who it's for

General practice veterinarians and veterinary oncology providers treating dogs with lymphoma.

Founders

Wesley Wierson

Founder

I am a scientist and entrepreneur applying my expertise in gene editing towards solving consumer level problems in society, first focused on building curative cancer therapies for pets, and eventually their owners. Through my time at LEAH Labs, I've also found a passion for biotech business model innovation through regulatory arbitrage - e.g. CAR-T in pets is regulated by USDA, not FDA, thus we can get to market 2-3x faster and for 500x less capital than human CAR-T

LinkedIn · X